http://www.fpnotebook.com/
Human Papilloma Virus VaccineAka: Quadrivalent Human Papillomavirus Vaccine, HPV Vaccine, Gardasil
- Indications
- Prevention of Cervical Dysplasia
- Females routinely at age 12 and catch-up age <26 years
- Mechanism
- Mixture of primary capsid proteins of 4 HPV types
- Two low risk HPV types (but cause most Genital Warts)
- HPV 6
- HPV 11
- Two high risk HPV types
- HPV 16
- HPV 18
- Contraindications
- Pregnancy
- Anaphylaxis to yeast
- Adverse Effects
- Local pain at injection site: 80%
- Local redness or swelling: 25%
- Fever
- Low grade in 10%
- Over 102 degrees in 1.4%
- Dosings
- Intramuscular Injection
- Schedule: 0, 2, and 6 months
- Cost
- Three doses: $440 (covered by most U.S. insurance plans)
- References
- Goeser (2007) Am Fam Physician 76:573-4
Human Papilloma Virus Vaccine (C1512511) | |
|---|---|
| Definition (NCI) | A recombinant vaccine of different types of HPV proteins which are well-conserved within types with a significant inter-type variation. |
| Definition (HL7V3.0) | human papilloma virus vaccine |
| Concepts | Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121) , Immunologic Factor (T129) |
| MSH | D053918 |
| English | HPV, HPV Vaccine, HPV Vaccines, Human Papilloma Virus Vaccine, Human Papilloma Virus Vaccines, Human papillomavirus vaccine, Human Papillomavirus Vaccines |
| Spanish | vacuna anti-papilomavirus humano |
| Parent Concepts | Vaccines administered (code = CVX)(parenteral, unless oral is noted) (C1547693), VaccineType (C1554000), Vaccines (C0042210), Viral Vaccines (C0042742) |
| Sources | HL7V2.5, HL7V3.0, MSH, MTH, NCI, SCTSPA, SNOMEDCT Derived from the NIH UMLS (Unified Medical Language System) |
Gardasil (C1721787) | |
|---|---|
| Concepts | Pharmacologic Substance (T121) , Immunologic Factor (T129) |
| MSH | C512720 |
| English | Gardasil, Merck brand of HPV quadrivalent vaccine |
| Sources | MSH, NCI, PDQ Derived from the NIH UMLS (Unified Medical Language System) |
